MIRANI, MARCO
MIRANI, MARCO
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
2023 S. Piccini, G. Favacchio, C. Panico, E. Morenghi, F. Folli, G. Mazziotti, A.G. Lania, M. Mirani
AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
2023 C. Berra, R. Manfrini, M. Mirani, L. Bucciarelli, A.S. Zakaria, S. Piccini, R. Ghelardi, M.E. Lunati, S. Rodovalho, F. Bifari, P. Fiorina, F. Folli
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
2022 M.E. Lunati, V. Cimino, A. Gandolfi, M. Trevisan, L. Montefusco, I. Pastore, C. Pace, N. Betella, G. Favacchio, M. Bulgheroni, L. Bucciarelli, G. Massari, C. Mascardi, A. Girelli, P.S. Morpurgo, F. Folli, L. Luzi, M. Mirani, B. Pintaudi, F. Bertuzzi, C. Berra, P. Fiorina
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study
2020 S.B. Solerte, F. D’Addio, R. Trevisan, E. Lovati, A. Rossi, I. Pastore, M. Dell’Acqua, E. Ippolito, C. Scaranna, R. Bellante, S. Galliani, A.R. Dodesini, G. Lepore, F. Geni, R.M. Fiorina, E. Catena, A. Corsico, R. Colombo, M. Mirani, C. De Riva, S.E. Oleandri, R. Abdi, J.V. Bonventre, S. Rusconi, F. Folli, A. Di Sabatino, G. Zuccotti, M. Galli, P. Fiorina
Reply to letter to the editor by Bonaventura et al
2019 C.C. Berra, F. De Fazio, E. Azzolini, M. Albini, F. Zangrandi, M. Mirani, S. Garbossa, R. Guardado-Mendoza, G. Condorelli, F. Folli
Hypoglycemia and hyperglycemia are risk factors for falls in the hospital population
2019 C. Berra, F. De Fazio, E. Azzolini, M. Albini, F. Zangrandi, M. Mirani, S. Garbossa, R. Guardado-Mendoza, G. Condorelli, F. Folli